Skip to main content
Terug
REGN logo

Regeneron Pharmaceuticals, Inc.

Datakwaliteit: 100%
REGN
NASDAQ Healthcare Biotechnology
€ 749,47
▲ € 7,78 (1,05%)
Marktkapitalisatie: 77,87B
Dagbereik
€ 744,02 € 757,98
52-Weeksbereik
€ 476,49 € 821,11
Volume
469.597
50D / 200D Gem.
€ 766,57 / € 651,78
Vorige Slotkoers
€ 741,69

Quick Summary

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (631 peers)

Metriek Aandeel Sector Mediaan
P/E 17,3 0,2
P/B 2,5 3,0
ROE % 14,9 3,6
Net Margin % 31,4 3,8
Rev Growth 5Y % -2,8 10,0
D/E 0,1 0,2

Koersdoel Analisten

Hold
€ 862,74 +15.1%
Low: € 700,00 High: € 1.057,00
Forward K/W
16,52
Forward WPA
€ 45,38
WPA Groei (sch.)
+0,0%
Omzet Sch.
15,70B

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 71,97
€ 64,90 – € 79,90
 21,24B 2
FY2029 € 67,38
€ 60,76 – € 74,80
 20,18B 4
FY2028 € 60,83
€ 48,91 – € 72,26
 18,70B 6

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-01-30 € 10,74 € 11,44 +6,5%
2025-10-28 € 9,65 € 11,83 +22,6%
2025-08-01 € 8,43 € 12,89 +52,9%
2025-04-29 € 8,62 € 8,22 -4,6%
2025-02-04 € 11,21 € 12,07 +7,7%
2024-10-31 € 11,69 € 12,46 +6,6%
2024-08-01 € 10,61 € 11,56 +9,0%
2024-05-02 € 10,17 € 9,55 -6,1%

Dividend History

1 yr streak

Yield

0,00%

Payout Ratio

0,08%

Growth (3Y)

N/A

Growth (5Y)

N/A

Ex-Date Payment Date Amount Yield
Feb 20, 2026 Mar 05, 2026 € 0,94 0,46%
Nov 20, 2025 Dec 05, 2025 € 0,88 0,48%
Aug 18, 2025 Sep 03, 2025 € 0,88 0,46%
May 20, 2025 Jun 06, 2025 € 0,88 0,29%
Feb 20, 2025 Mar 20, 2025 € 0,88 0,13%

Belangrijkste Punten

Revenue declined -2,81% annually over 5 years
ROE of 14,87% — decent returns on equity
Net margin of 31,41% shows strong profitability
Debt/Equity of 0,09 — conservative balance sheet
Generating 4,08B in free cash flow
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 3,80%

Groei

Revenue Growth (5Y)
-2,81%
Revenue (1Y)0,99%
Earnings (1Y)2,09%
FCF Growth (3Y)5,48%

Kwaliteit

Return on Equity
14,87%
ROIC7,90%
Net Margin31,41%
Op. Margin24,95%

Veiligheid

Debt / Equity
0,09
Current Ratio4,13
Interest Coverage81,69

Waardering

P/E Ratio
17,29
Forward P/E16,52
P/B Ratio2,49
EV/EBITDA21,65
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 0,99% Revenue Growth (3Y) 4,57%
Earnings Growth (1Y) 2,09% Earnings Growth (3Y) 6,74%
Revenue Growth (5Y) -2,81% Earnings Growth (5Y) -13,58%
Profitability
Revenue (TTM) 14,34B Net Income (TTM) 4,50B
ROE 14,87% ROA 11,11%
Gross Margin 85,35% Operating Margin 24,95%
Net Margin 31,41% Free Cash Flow (TTM) 4,08B
ROIC 7,90% FCF Growth (3Y) 5,48%
Safety
Debt / Equity 0,09 Current Ratio 4,13
Interest Coverage 81,69
Dividends
Dividend Yield 0,00% Payout Ratio 0,08%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years 1 yrs
Valuation
P/E Ratio 17,29 Forward P/E 16,52
P/B Ratio 2,49 P/S Ratio 5,43
PEG Ratio 3,38 Forward PEG N/A
EV/EBITDA 21,65 Fwd EV/EBITDA 11,36
Forward P/S 4,96 Fwd Earnings Yield 6,05%
FCF Yield 5,24%
Market Cap 77,87B Enterprise Value 77,46B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 14,34B 14,20B 13,12B 12,17B 16,07B
Net Income 4,50B 4,41B 3,95B 4,34B 8,08B
EPS (Diluted) 41,48 38,34 34,77 38,22 71,97
Gross Profit 12,24B 12,23B 10,87B 10,47B 13,35B
Operating Income 3,58B 3,99B 4,35B 5,39B 8,95B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 40,56B 37,76B 33,08B 29,21B 25,43B
Total Liabilities 9,30B 8,41B 7,11B 6,55B 6,67B
Shareholders' Equity 31,26B 29,35B 25,97B 22,66B 18,77B
Total Debt 2,71B 2,70B 2,70B 2,70B 2,70B
Cash & Equivalents 3,12B 2,49B 2,73B 3,11B 2,89B
Current Assets 18,02B 18,66B 19,48B 15,88B 14,01B
Current Liabilities 4,37B 3,94B 3,42B 3,14B 3,93B